中国实验血液学杂志最新文献

{"title":"[Analysis of Related Factors for Graft Failure in Umbilical Cord Blood Transplantation for Hematological Diseases].","authors":"Xin-Chen Fang, Chao-Jie Hu, Zhi-Wei Wu, Xiao Xiao, Xiu-Cai Xu, Pan-Pan Huang, Xiang Wan","doi":"10.19746/j.cnki.issn1009-2137.2026.04.038","DOIUrl":"https://doi.org/10.19746/j.cnki.issn1009-2137.2026.04.038","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the early influencing factors of primary graft failure (PGF) following umbilical cord blood transplantation (UCBT).</p><p><strong>Methods: </strong>A retrospective analysis was conducted on the clinical data of 40 patients who underwent UCBT and developed PGF at the First Affiliated Hospital of the University of Science and Technology of China from June 1, 2017 to July 30, 2024. Additionally, 139 patients with successful transplantation during the same period were selected as a control group. Donor chimerism was assessed on day 7, 14, 21, and 30 post-transplantation, and lymphocyte subsets were examined on day 30 post-transplantation.</p><p><strong>Results: </strong>There were no significant differences between the two groups in baseline characteristics such as disease types, sex, age, and HLA matching status (all <i>P</i>>0.05). The number of infused CD34⁺ cells in the graft failure group was lower than that in the graft success group (<i>P</i><0.05), and the donor chimerism at each detection time point was significantly lower than that in the graft success group (<i>P</i><0.001). When the chimerism was lower than 32.6% on day 7 post-transplantation, the sensitivity and specificity for predicting graft failure were 0.825 and 0.884, respectively. The median proportion of CD3⁺CD4⁺CD8^- T cells in lymphocytes in the graft failure group was 12.4% (3.3%-29.8%), which was significantly lower than that in the graft success group ［19.9% (4.4%-56.8%)］ (<i>P</i>=0.001).</p><p><strong>Conclusion: </strong>The chimerism on day 7 post-UCBT is a potential indicator for predicting graft failure. A lower number of CD34⁺ cells in the umbilical cord blood stem cells used for transplantation and a lower level of CD3⁺CD4⁺CD8^- T cells in the early stage after transplantation may be related to graft failure.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"34 4","pages":"1189-1195"},"PeriodicalIF":0.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149070172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Changes of Peripheral Blood Ferritin, Coagulation Factors, IL-17A and IL-12p70, and Their Predictive Values for Risk of Early Death and Differentiation Syndrome in Patients with Newly Diagnosed APL].","authors":"Wen-Fang Zhang, Juan Zhou","doi":"10.19746/j.cnki.issn1009-2137.2026.04.007","DOIUrl":"https://doi.org/10.19746/j.cnki.issn1009-2137.2026.04.007","url":null,"abstract":"<p><strong>Objective: </strong>To explore changes of peripheral blood serum ferritin (SF), coagulation factors, interleukin (IL)-17A and IL-12p70 in patients with newly diagnosed acute promyelocytic leukemia (APL), and analyze their predictive values for risk of early death and differentiation syndrome.</p><p><strong>Methods: </strong>A total of 80 newly diagnosed APL patients who were admitted to our hospital from January 2019 to December 2023 were enrolled as the APL group, and 80 healthy controls during the same period were selected as the control group. The levels of white blood cell count (WBC), platelet count (PLT), fibrinogen degradation products (FDP), SF, FⅡ：C, FⅤ：C, FⅧ：C, FⅩ：C, IL-17A and IL-12p70 were compared between the two groups. According to presence or absence of early death, patients in APL group were further divided into survival group and death group, and the levels of the above indices between the two subgroups were compared. Based on whether differentiation syndrome occurred, patients in the APL group were divided into occurrence group and non-occurrence group, and the levels of the above indices between the two subgroups were compared. The predictive values of different indices for early death and differentiation syndrome were analyzed by receiver operating characteristic (ROC) curves.</p><p><strong>Results: </strong>The levels of SF, IL-17A and IL-12p70 were abnormally elevated, while FⅡ：C, FⅤ：C and FⅩ：C were reduced in APL patients. Compared with the survival group, the levels of WBC, FDP, SF, IL-17A and IL-12p70 increased but PLT, FⅡ：C and FⅩ：C decreased in the death group (all <i>P</i> < 0.05). However, there were no statistically significant differences in the levels of FⅤ：C and FⅧ：C between the two groups (<i>P</i> >0.05). Compared with the non-occurrence group, the changes in the above indices in the occurrence group were the same as those in the death group. The results of ROC curve analysis showed that AUC values of SF, FⅡ：C, FⅩ：C, IL-17A and IL-12p70 for predicting early death were 0.801, 0.752, 0.795, 0.771 and 0.729, respectively, while for predicting differentiation syndrome were 0.739, 0.694, 0.792, 0.701 and 0.692, respectively.</p><p><strong>Conclusion: </strong>The SF, coagulation factors, IL-17A and IL-12p70 all have certain predictive value in early death and differentiation syndrome.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"34 4","pages":"979-985"},"PeriodicalIF":0.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149070190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Analysis of Genotyping and Polymorphism of 104 RhD Variant Blood Donors in Tianjin].","authors":"Li-Na Wu, Lei Ma, Shuang-Yu Li, Shi-Ping An, Jing-Hui Chong, Yang Yang, Ying Zhao, Xian Huang, Jin-Hui Xie","doi":"10.19746/j.cnki.issn1009-2137.2026.04.035","DOIUrl":"https://doi.org/10.19746/j.cnki.issn1009-2137.2026.04.035","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the genotyping and polymorphism of RhD variants in Tianjin region, providing reference for guiding clinical transfusion and partial pregnatal testing.</p><p><strong>Methods: </strong>Blood samples were collected from donors with serologically weak D phenotypes through laboratory testing from 2021 to 2024 at the Tianjin Blood Center. <i>RHD</i> genotyping was performed by using SSP-PCR. For unresolved genotypes, DNA sequence-based typing (SBT) was applied for gene sequencing.</p><p><strong>Results: </strong>A total of 104 RhD variants were statistically analyzed, and 72 were successfully indentified by <i>RHD</i> gene typing. Common variants included weak D type 15 (37 cases), DEL 1227A (16 cases), and DVI type (13 cases). Sequencing resolved 32 cases, predominantly weak D type 33. Two novel <i>RHD</i> genotypes not yet cataloged by ISBT were identified: one carried a homozygous 1100T>A mutation in exon 8, and the other showed a homozygous 526G>A mutation in exon 4 of the <i>RHD</i> gene.</p><p><strong>Conclusion: </strong><i>RHD</i> exon structures exhibit polymorphism. The predominant RhD variants were weak D type 15, DEL 1227A, and weak D type 33 identified among blood donors in Tianjin.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"34 4","pages":"1174-1177"},"PeriodicalIF":0.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149070195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Research on the Immunotherapy of T Cell Exhaustion in Multiple Myeloma --Review].","authors":"Ya Nan Cai, Xu Zhang Lu, Min Zhou","doi":"10.19746/j.cnki.issn1009-2137.2026.04.044","DOIUrl":"https://doi.org/10.19746/j.cnki.issn1009-2137.2026.04.044","url":null,"abstract":"<p><p>Multiple myeloma (MM) has strong heterogeneity and is still an incurable tumor. The new immunotherapy represented by bispecific antibody (BsAb) and chimeric antigen receptor T-cell immunotherapy (CAR-T) has shown significant efficacy in MM treatment. However, these therapies directly utilize T cell activity, and the efficacy is affected by the functional state of T cells. T cell exhaustion (Tex), one of the important characteristics of MM, is closely related to the progression, drug resistance, recurrence, and poor prognosis of MM. Therefore, Tex is the key factor limiting the efficacy of BsAb and CAR-T technologies. This article reviews the latest research progress on the mutual influence between Tex and these therapies.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"34 4","pages":"1226-1229"},"PeriodicalIF":0.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149070269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Study and Application of Rabbit Anti-Human CD38 Polyclonal Antibodies in Eliminating Daratumumab Interference in the Indirect Antiglobulin Test].","authors":"Liang-Zi Zhang, Hua Xu, Lu Li, Yin-Ze Zhang","doi":"10.19746/j.cnki.issn1009-2137.2026.04.034","DOIUrl":"https://doi.org/10.19746/j.cnki.issn1009-2137.2026.04.034","url":null,"abstract":"<p><strong>Objective: </strong>To prepare rabbit anti-human CD38 polyclonal antibodies capable of masking CD38 antigens on the surface of red blood cells (RBCs), thereby eliminating the interference of daratumumab (DARA) in pretransfusion compatibility testing.</p><p><strong>Methods: </strong>Rabbit anti-human CD38 polyclonal antibodies were generated by immunizing New Zealand white rabbits with recombinant human CD38 extracellular domain His-tag fusion protein (hCD38-His). Antibody purity and molecular weight were assessed by SDS-PAGE. The direct antiglobulin test (DAT) was used to evaluate reactivity with antiglobulin reagents, while the indirect antiglobulin test (IAT) was applied to assess the efficacy of eliminating DARA interference and its impact on irregular antibodies detection. The effect of rabbit-derived anti-human CD38 polyclonal antibody on blood group antigen detection results was evaluated by detecting major blood group antigens on red blood cells.</p><p><strong>Results: </strong>SDS-PAGE analysis showed that the rabbit-derived anti-human CD38 polyclonal antibodies had high purity with molecular weights consistent with theoretical expectations. RBCs treated with rabbit anti-human CD38 polyclonal antibody yielded negative results in DAT, suggesting no cross-reactivity with antiglobulin reagents. IAT results demonstrated that masking RBC CD38 antigens with rabbit anti-human CD38 polyclonal antibodies effectively eliminated DARA-induced interference without compromising the detection of low-titer irregular antibodies. Furthermore, testing of major blood group antigens revealed that antibody treatment did not interfere with blood group antigen identification.</p><p><strong>Conclusion: </strong>Rabbit anti-human CD38 polyclonal antibodies can stably and effectively eliminate DARA-induced interference in pretransfusion compatibility testing, without affecting the detection of RBC blood group antigens or irregular antibodies. This method is simple to operate and provides a new reliable option for clinical pretransfusion testing.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"34 4","pages":"1165-1173"},"PeriodicalIF":0.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149070445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Expression Level and Function of <i><i>UBE2QL1</i></i> in Multiple Myeloma].","authors":"Jin Wang, Hui-Hui Liu, Xiao-Ying Yang, Wei-Wei Xie, Shuang-Lian Xie, Wen-Qiong Wang, Yi-Ming Zhao, Yu-Jun Dong","doi":"10.19746/j.cnki.issn1009-2137.2026.04.016","DOIUrl":"https://doi.org/10.19746/j.cnki.issn1009-2137.2026.04.016","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the expression level of <i>UBE2QL1</i> in multiple myeloma (MM) and its correlation with disease progression and prognosis, as well as to elucidate the biological role of <i>UBE2QL1</i> in MM through <i>in vitro</i> cell experiments.</p><p><strong>Methods: </strong>Bioinformatics analysis was used to explore the expression level of <i>UBE2QL1</i> in MM and its impact on prognosis. Concurrently, a polyclonal antibody against <i>UBE2QL1</i> was synthesized, and its specificity was confirmed through mass spectrometry. The expression level of <i>UBE2QL1</i> in MM cell lines and primary bone marrow samples was validated using qRT-PCR and Western blot, followed by comparative analysis with the corresponding clinical data. Subsequently, the <i>UBE2QL1</i> gene was knocked down in the MM cell lines NCI-H929 and MM.1S. to verify its regulatory effects on MM cell functions.</p><p><strong>Results: </strong>Analyses based on the Hemap, DepMap (CCLE), and GEO databases revealed that <i>UBE2QL1</i> was highly expressed in MM, and its expression level was closely associated with disease progression and poor prognosis.<i>In vitro</i> experiments further confirmed the elevated expression of <i>UBE2QL1</i> in MM cell lines and primary bone marrow samples from patients, showing a positive correlation with the proportion of plasma cells. Knockdown of <i>UBE2QL1</i> in MM cell lines inhibited cell proliferation, promoted cell apoptosis, and improved cellular sensitivity to widely used therapeutic agents, including bortezomib, carfilzomib, and lenalidomide.</p><p><strong>Conclusion: </strong><i>UBE2QL1</i> is highly expressed in MM and is closely associated with adverse disease progression and poor prognosis. Knockdown of <i>UBE2QL1</i> <i>in vitro</i> can effectively inhibit MM cell proliferation, promote apoptosis, and enhance cellular sensitivity to therapeutic agents. Monitoring the expression level of <i>UBE2QL1</i> may help to more accurately assess the prognosis of MM patients and provide a reference for therapeutic decision-making.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"34 4","pages":"1036-1045"},"PeriodicalIF":0.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149070080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Serological and Genotypic Analysis of a Family with B(A) Subtype].","authors":"Dong-Mei Ge, Hai-Yan Wang, Li-Qin Wang, Zhong-Cui Jing, Shan-Shan Yu, Shu-Chao Zhang","doi":"10.19746/j.cnki.issn1009-2137.2026.04.024","DOIUrl":"https://doi.org/10.19746/j.cnki.issn1009-2137.2026.04.024","url":null,"abstract":"<p><strong>Objective: </strong>To perform blood group typing and genotyping on the proband with weak ABO antigen expression and his family members, thereby clarifying the ABO phenotype and the molecular genetic basis of the weak antigen expression.</p><p><strong>Methods: </strong>Serological ABO blood group typing was performed on the proband and four family members. PCR amplification of exons 6 and 7 of the <i>ABO</i> gene was carried out followed by direct sequencing analysis, and haplotypes were further confirmed by clonal sequencing.</p><p><strong>Results: </strong>Direct sequencing results revealed a c.640A＞G single-nucleotide heterozygous mutation in exon 7 of the proband's <i>ABO</i> gene. This mutation was confirmed by clonal sequencing and haplotype analysis to be located on the background of the <i>B.01</i> allele, which was consistent with the characteristics of the <i>ABO*BA.04</i> allele. Among the five members of the family, three carried the <i>BA.04</i> allele. Specifically, the proband had a genotype of <i>ABO*BA.04/O.01.01</i> with a serological phenotype of AwB; both the proband's son and eldest daughter had a genotype of <i>ABO*BA.04/A1.01</i> with a serological phenotype of ABw.</p><p><strong>Conclusion: </strong>When the <i>ABO*BA.04</i> allele is heterozygous with other common alleles, different ABO weak antigen phenotypes can be produced. Serological testing combined with genotyping technology facilitates the accurate identification of ABO weak antigen phenotypes.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"34 4","pages":"1101-1105"},"PeriodicalIF":0.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149070373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Research Progress on the Role of Bone Marrow Mesenchymal Stem Cells in Drug Resistance and Relapse of Acute Myeloid Leukemia --Review].","authors":"Xi-Ru Peng, Juan Cheng, Li Zhao","doi":"10.19746/j.cnki.issn1009-2137.2026.04.045","DOIUrl":"https://doi.org/10.19746/j.cnki.issn1009-2137.2026.04.045","url":null,"abstract":"<p><p>With the development of new drug research and transplantation techniques, significant progress has been made in the treatment of acute myeloid leukemia (AML). However, most patients still suffer from clinical relapse. Bone marrow mesenchymal stem cells (BM-MSCs), as crucial cellular components of the bone marrow microenvironment, contribute to AML drug resistance and relapse by promoting the proliferation of AML cells and reducing their sensitivity to chemotherapeutic agents. This article reviews the specific mechanisms through which AML cells reprogram BM-MSCs to mediate drug resistance and relapse, as well as recent research advances in targeting BM-MSCs for AML treatment, providing a theoretical basis for AML therapy from the perspective of regulating the bone marrow microenvironment.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"34 4","pages":"1230-1234"},"PeriodicalIF":0.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149070387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Prediction Model of Systemic Lupus Erythematosus Based on Machine Learning Algorithms].","authors":"Jin Zhang, Tai-Qiang Zhao, Juan Zhang","doi":"10.19746/j.cnki.issn1009-2137.2026.04.022","DOIUrl":"https://doi.org/10.19746/j.cnki.issn1009-2137.2026.04.022","url":null,"abstract":"<p><strong>Objective: </strong>To establish disease prediction models using 6 distinct machines learning algorithms, and to screen diagnostic markers for systemic lupus erythematosus(SLE) by detecting platelet aggregation rates via platelet aggregation assays and comparing their differences between SLE patients and healthy controls.</p><p><strong>Methods: </strong>A cross-sectional study design was adopted, retrospective data were gathered from 123 female patients diagnosed with SLE who attended Sichuan Provincial People's Hospital between July 2022 and July 2025, alongside data from 64 female healthy controls. Platelet aggregation rates induced by four agonists, including adenosine diphosphate(ADP), arachidonic acid(AA), epinephrine(EPI) and collagen(COL), were quantified by optical transmission turbidimetry. Six diagnostic models for SLE were further established, and their diagnostic efficiencies were evaluated.</p><p><strong>Results: </strong>Due to missing data, the valid sample size was 121 among the 123 patients with SLE. The multivariate logistic regression analysis revealed that both AA and ADP serve as independent risk factors for patients with SLE(<i>P</i><0.05). Among the evaluated predictive models, the XGBoost model exhibited the highest area under the curve(AUC=0.984, 95%<i>CI</i> : 0.969-1.000). Furthermore, the DCA curve indicated that the XGBoost model provided the greatest net benefit across the examined threshold probabilities. Feature importance assessment within the XGBoost framework identified AA as the most significant predictor of SLE, followed sequentially by COL, ADP, and EPI.</p><p><strong>Conclusion: </strong>The diagnostic model for SLE patients, developed utilizing the XGBoost algorithm, exhibits a robust predictive performance. When integrated with clinical features, this model has the potential to enhance diagnostic accuracy and efficiency, thereby presenting significant value for clinical application.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"34 4","pages":"1085-1091"},"PeriodicalIF":0.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149070222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[A Study on Influence of Hematocrit on Platelet Yield].","authors":"Xiao-Yan Yu, Cun-Hao Ma, Li-Juan Liu, Ya-Ru Li, Qian Zhou","doi":"10.19746/j.cnki.issn1009-2137.2026.04.027","DOIUrl":"https://doi.org/10.19746/j.cnki.issn1009-2137.2026.04.027","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the influence of hematocrit (HCT) on platelet yield.</p><p><strong>Methods: </strong>Retrospective analysis was conducted on data from apheresis donors from January to February 2024, including height, weight, HCT, pre-donation platelet (pre-PLT) count, processed blood volume, collection duration. Differences in HCT, processed blood volume, and collection duration among platelet concentrate with varying counts were compared.</p><p><strong>Results: </strong>The qualification rates of single-unit, 1.5-unit, and double-unit PLT products were 100%, 83.94% and 94.09%, respectively, which exceeded the national standard (qualification rate should not be lower than 75%). The factors influencing the PLT yield were HCT, body weight and pre-PLT count. 50% of double-unit platelet products had counts exceeding 1 101×10⁹/L, while the remaining 50% fell within the range of 985×10⁹/L to 1 100×10⁹/L. Under equivalent height, weight, and pre-PLT count conditions, when HCT was 44%, double-unit platelet concentrate counts met the standard, with reduced processing blood volume and collection time compared to over-standard products.</p><p><strong>Conclusion: </strong>HCT is one of the critical factors influencing platelet yield. For double-unit apheresis, adjusting HCT to no lower than 44% in donors with high HCT ensures compliance with product quality standards while maintaining donor safety, particularly for individuals with low body weight, poor blood flow, or susceptibility to donation reactions.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"34 4","pages":"1121-1124"},"PeriodicalIF":0.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149070203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}